The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...
You and your family are our top priority. At Fred Hutch Cancer Center, we offer comprehensive and compassionate care — personalized to you. You'll have access to the latest treatment options, clinical ...
The Phase 1b/2 SCLC trial and Phase 2 VIRO-25 trial are actively enrolling in dose escalation cohorts with an aim to optimize efficacy, safety, and tolerability of Olvi-Vec. The trials are being ...
Lung cancer patients receiving immunochemotherapy earlier in the day had a 52% lower risk of progression in a new medical ...
If you smoke and want to quit, call the national quit line at 1-800-784-8669 to speak with a confidential coach. In what ...
Small cell lung cancer (SCLC) is one of the most aggressive forms of lung cancer, with a five-year survival rate of only 5%.
TipRanks on MSN
Kelun-Biotech’s ADC-PD-1 combo wins breakthrough therapy status in first-line lung cancer
An announcement from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( ($HK:6990) ) is now available. Sichuan Kelun-Biotech announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback